Atrium Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-684.63	-322.3	-212.22	-174	-118.01
Depreciation & Amortization	4.15	2.78	2.1	1.39	0.64
Stock-Based Compensation	97.84	51.36	38.22	27.14	17.06
Other Adjustments	-8.14	-18.15	-8.3	2.13	0.86
Changes in Accounts Payable	3.8	-0.35	4.17	18.32	6.04
Changes in Accrued Expenses	90.74	24.86	0.74	2.25	5.79
Changes in Unearned Revenue	-8.62	-10.32	62.99	-5.12	-4.44
Changes in Other Operating Activities	-145.58	-28.75	-6.77	-8.38	-2.74
Operating Cash Flow	-650.44	-300.87	-119.06	-136.27	-94.81
Operating Cash Flow Growth	-	-	-	-	-
Capital Expenditures	-13.32	-7.07	-4.23	-2.82	-3.74
Purchases of Investments	-1,107	-1,434	-461	-355.84	-85.36
Proceeds from Sale of Investments	1,086	586.4	335.16	168.71	6.58
Other Investing Activities	-4.07	-	-	-	-
Investing Cash Flow	-38.04	-854.2	-130.07	-189.96	-82.52
Issuance of Common Stock	863.4	1,192	93.86	346.17	176.32
Net Common Stock Issued (Repurchased)	863.4	1,192	93.86	346.17	176.32
Other Financing Activities	-12.41	-	-	-	-
Financing Cash Flow	850.99	1,192	93.86	346.17	176.32
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.14	-	-	-	-
Net Cash Flow	162.65	37.29	-155.27	19.95	-1.01
Free Cash Flow	-663.76	-307.94	-123.29	-139.09	-98.55
Free Cash Flow Growth	-	-	-	-	-
FCF Margin	-3539.11%	-2825.88%	-1289.67%	-1507.92%	-1056.76%
Free Cash Flow Per Share	-4.82	-2.76	-1.69	-2.67	-2.38
Levered Free Cash Flow	-753.46	-341.15	-153.22	-168.36	-116.47
Unlevered Free Cash Flow	-814.77	-397.78	-176.6	-173.28	-116.51